News about "precision oncology"

Boehringer Ingelheim Launches 3 Phase 3 Trials to Advance Precision Oncology in Hard-to-Treat Cancers

Boehringer Ingelheim Launches 3 Phase 3 Trials to Advance Precision Oncology in Hard-to-Treat Cancers

Boehringer Ingelheim has initiated 3 phase 3 oncology trials, including DAREON-Lung-1 and DAREON-NEC-1, to evaluate obrixtamig as a DLL3 biomarker-guided treatment approach for hard-to-treat cancers.

Precision Oncology | 23/06/2026 | By News Bureau

Sophia Genetics Signs MoU with Memorial Sloan Kettering Cancer Center

Sophia Genetics Signs MoU with Memorial Sloan Kettering Cancer Center

Sophia Genetics has signed a strategic collaboration Memorandum of Understanding (MoU) with Memorial Sloan Kettering Cancer Center to establish a next-generation precision medicine hub.

Precision Oncology | 08/06/2026 | By News Bureau 106

Colorectal Cancer Alliance, GCAR Launch Adaptive KLEOS Trial Platform to Accelerate Colorectal Cancer Treatment Development

Colorectal Cancer Alliance, GCAR Launch Adaptive KLEOS Trial Platform to Accelerate Colorectal Cancer Treatment Development

The Colorectal Cancer Alliance and the Global Coalition for Adaptive Research have partnered to launch KLEOS, a pioneering adaptive clinical trial platform designed to accelerate the development of new therapies for colorectal cancer and improve patient outcomes.

Precision Oncology | 01/06/2026 | By News Bureau

Chugai Secures World's First Tumour-Agnostic Approval for ALK Inhibitor Alecensa in Japan

Chugai Secures World's First Tumour-Agnostic Approval for ALK Inhibitor Alecensa in Japan

Chugai Pharmaceutical has received regulatory approval in Japan for the expanded use of Alecensa (alectinib) in advanced or recurrent ALK fusion-positive solid tumours, marking the world’s first tumour-agnostic approval for an ALK inhibitor.

Precision Oncology | 19/05/2026 | By News Bureau 119

Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954

Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954

Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.

Precision Oncology | 12/05/2026 | By News Bureau 181

Illumina, Labcorp Expand Partnership to Advance Precision Oncology

Illumina, Labcorp Expand Partnership to Advance Precision Oncology

Illumina and Labcorp have expanded their collaboration to strengthen precision oncology through wider use of next-generation sequencing (NGS) technologies.

Precision Oncology | 20/03/2026 | By Darshana 176


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members